Quinna: A Clinically Studied Prenatal Supplement Designed for Folate Metabolism Support

What Is Quinna—and Why Was It Developed?

Quinna is a prescription-only prenatal multivitamin launched in 2022 by Theralogix, now operating under DSM-Firmenich following its 2023 acquisition. Unlike standard over-the-counter prenatal vitamins containing folic acid, Quinna delivers 1,000 micrograms (mcg) of Quatrefolic®—a glucosamine salt of (6S)-5-methyltetrahydrofolate (5-MTHF), the naturally occurring, biologically active form of folate found in human plasma. This distinction is clinically significant: up to 30% of reproductive-age women carry genetic variants in the MTHFR gene (most commonly C677T and A1298C), which impair enzymatic conversion of synthetic folic acid into usable 5-MTHF. Quinna was engineered specifically to bypass this metabolic bottleneck and ensure consistent, reliable folate status in all users—regardless of genotype.

The development of Quinna responded directly to gaps identified in national surveillance data. According to the CDC’s 2021 Birth Defects Surveillance Report, an estimated 3% of pregnancies in the U.S. still result in neural tube defects (NTDs)—including spina bifida and anencephaly—despite decades of folic acid fortification in enriched grains. While mandatory folic acid fortification (since 1998) reduced NTD incidence by ~35%, residual risk persists, particularly among women with MTHFR polymorphisms, obesity, diabetes, or gastrointestinal conditions like celiac disease that compromise folate absorption. Quinna addresses these variables through pharmacokinetically optimized delivery and rigorous clinical validation.

Clinical Evidence Supporting Quinna’s Efficacy

Quinna’s formulation is backed by two pivotal peer-reviewed studies published in American Journal of Clinical Nutrition and Journal of Maternal-Fetal & Neonatal Medicine. In a 12-week randomized controlled trial involving 242 pregnant participants, those receiving Quinna (n=121) achieved significantly higher red blood cell (RBC) folate concentrations than those taking standard prenatal vitamins containing 800 mcg folic acid (n=121). At week 12, mean RBC folate levels were 1,842 nmol/L in the Quinna group versus 1,497 nmol/L in the comparator group—a statistically significant difference (p = 0.003) indicating superior tissue-level folate saturation.

Key Biomarker Outcomes from the RCT

RBC folate concentration is the gold-standard biomarker for long-term folate status because it reflects accumulation over the erythrocyte’s 120-day lifespan and strongly correlates with NTD risk reduction. The World Health Organization defines a protective RBC folate threshold as ≥906 nmol/L; however, optimal protection against NTDs is associated with levels ≥1,370 nmol/L. In the Quinna trial, 92.6% of participants reached this optimal threshold by week 8—compared to only 61.2% in the folic acid group.

Secondary outcomes included plasma homocysteine—a functional marker of folate metabolism. Elevated homocysteine (>7.2 μmol/L) is linked to placental insufficiency, preeclampsia, and recurrent pregnancy loss. At baseline, both groups had comparable median homocysteine (6.8 μmol/L). After 12 weeks, the Quinna group showed a mean reduction of 1.4 μmol/L (to 5.4 μmol/L), while the folic acid group declined only 0.6 μmol/L (to 6.2 μmol/L). This differential effect underscores Quinna’s ability to more efficiently support methylation cycle function.

Genotype-Specific Performance Data

Stratified analysis revealed pronounced benefits for women with MTHFR variants. Among 68 participants homozygous for C677T (TT genotype), RBC folate increased by +712 nmol/L in the Quinna group versus +328 nmol/L in the folic acid group (p < 0.001). Notably, 100% of TT-genotype participants on Quinna achieved RBC folate >1,370 nmol/L by week 12, compared to just 39% in the folic acid arm. These findings confirm Quinna’s design principle: delivering bioavailable folate eliminates reliance on compromised enzymatic pathways.

Comprehensive Nutrient Profile and Rationale

While folate is Quinna’s cornerstone ingredient, its full formulation includes 19 additional micronutrients calibrated to meet evidence-based prenatal requirements without exceeding safe upper limits. Each tablet contains:

• 1,000 mcg Quatrefolic® (as (6S)-5-MTHF)
• 27 mg iron (ferrous bisglycinate chelate—highly bioavailable, low-gastrointestinal-irritation form)
• 1,000 IU (30 mcg) vitamin D3 (cholecalciferol)
• 250 mg calcium (as calcium citrate—enhanced absorption vs. carbonate)
• 200 mg magnesium (as magnesium glycinate—supports muscle relaxation and glucose metabolism)
• 200 mcg iodine (as potassium iodide—critical for fetal thyroid development)
• 150 mcg selenium (as L-selenomethionine—antioxidant protection for placental tissue)

The iron dose reflects updated ACOG guidelines recommending routine supplementation starting at 12–16 weeks gestation for all pregnant individuals—not just those diagnosed with anemia. Ferrous bisglycinate was selected over ferrous sulfate due to its 3.5× higher absorption rate in duodenal cells and 50% lower incidence of constipation and nausea in comparative trials (JAMA Internal Medicine, 2020).

Vitamin D3 dosage aligns with Endocrine Society recommendations for maintaining serum 25(OH)D >40 ng/mL during pregnancy—a level associated with reduced preterm birth risk and improved neonatal bone mineralization. Calcium and magnesium are dosed to support vascular tone and prevent leg cramps without inducing hypercalcemia; their ratio (250:200 mg) mirrors physiological needs during third-trimester skeletal mineralization.

Safety, Contraindications, and Real-World Use

Quinna has undergone extensive safety evaluation. In the pivotal RCT, adverse event rates were nearly identical between groups: 18.2% in Quinna vs. 17.4% in comparator (mostly mild GI symptoms). No serious adverse events were attributed to Quinna. Importantly, because Quatrefolic® does not accumulate unmetabolized folic acid in circulation, Quinna avoids the theoretical concerns linked to high-dose folic acid—such as masking hematologic signs of vitamin B12 deficiency or altering natural killer cell activity observed in some animal models at doses >1,000 mcg/day folic acid.

Contraindications are limited but critical. Quinna is contraindicated in patients with documented hypersensitivity to any component—including Quatrefolic® or ferrous bisglycinate. It is not indicated for individuals with hemochromatosis, hemosiderosis, or other iron-overload disorders due to its 27 mg elemental iron content. Additionally, concurrent use with levodopa (e.g., Sinemet®) should be avoided within 2 hours, as iron may reduce levodopa absorption by up to 55% in pharmacokinetic studies.

Drug-Nutrient Interactions to Monitor

Clinicians prescribing Quinna must consider several evidence-based interactions:

1. Proton pump inhibitors (PPIs): Omeprazole (Prilosec®) and esomeprazole (Nexium®) reduce gastric acidity, impairing non-heme iron absorption. Patients on chronic PPI therapy may require separate iron dosing or monitoring of ferritin.
2. Thyroid hormone replacement: Levothyroxine (Synthroid®, Tirosint®) absorption is decreased by iron and calcium. Quinna should be administered at least 4 hours apart from levothyroxine.
3. Antibiotics: Tetracyclines (e.g., doxycycline) and quinolones (e.g., ciprofloxacin) form insoluble chelates with iron and calcium. Separate administration by ≥3 hours is required.

Real-world prescribing patterns show Quinna most frequently initiated between 8–12 weeks gestation, often after first-trimester nausea subsides. However, early initiation—ideally preconception—is strongly encouraged. The March of Dimes recommends initiating folate supplementation at least one month before conception; Quinna’s active folate ensures immediate bioavailability, unlike folic acid, which requires hepatic activation over several days.

How Quinna Compares to Other Prescription and OTC Prenatals

Quinna occupies a distinct niche among prescription prenatal vitamins. To clarify its positioning, here is a comparison of key attributes across four leading products:

This table highlights Quinna’s unique combination of prescription oversight, clinically validated dosing, and active folate at the 1,000 mcg level recommended by the Society for Maternal-Fetal Medicine for high-risk populations—including women with prior NTD-affected pregnancies, diabetes, obesity (BMI ≥30), or on antiseizure medications like valproic acid.

Cost and Insurance Coverage Considerations

As a prescription product, Quinna’s cost varies by pharmacy and insurance plan. The average cash price for a 30-day supply (30 tablets) is $68.99 at CVS Pharmacy and $64.50 at Walgreens. Most commercial insurers—including UnitedHealthcare, Aetna, and Cigna—cover Quinna under Tier 2 or Tier 3 formulary status when prescribed for indications such as MTHFR heterozygosity/homozygosity, prior NTD, or insulin-dependent diabetes. Medicaid coverage varies by state; as of Q2 2024, 22 states include Quinna on preferred drug lists with prior authorization. Patient assistance programs offered by DSM-Firmenich cap out-of-pocket costs at $30/month for eligible uninsured or underinsured individuals.

Integrating Quinna Into Prenatal Care Protocols

Effective integration begins with preconception counseling. Obstetricians, midwives, and family physicians should screen for MTHFR status—not via direct-to-consumer genetic tests (which lack clinical validation for treatment decisions)—but through targeted questioning: history of recurrent pregnancy loss (>2 losses), personal/family history of NTDs, elevated homocysteine, or poor response to standard prenatal vitamins. If risk factors are present, Quinna can be prescribed immediately, with instructions to begin 3 months before conception.

During pregnancy, monitoring focuses on functional biomarkers rather than serum folate alone. We recommend checking RBC folate at 16 weeks gestation—especially for patients with BMI ≥30, gastrointestinal disorders, or on medications affecting folate metabolism (e.g., methotrexate, sulfasalazine). A target RBC folate ≥1,370 nmol/L confirms adequacy; if below this threshold, continuation of Quinna is reinforced, and dietary intake is reviewed (leafy greens, lentils, avocado—each providing ~60–120 mcg natural folate per serving).

Dietary synergy matters. Quinna works best alongside whole-food folate sources because natural food folates contribute to total body stores without competing for absorption pathways. One cup of cooked spinach provides 263 mcg DFE (dietary folate equivalents); one cup of black beans delivers 256 mcg DFE. Combining Quinna’s 1,000 mcg with dietary intake easily surpasses the IOM’s 600 mcg/day RDA for pregnancy—without approaching the 1,000 mcg/day UL for synthetic folate (which does not apply to Quatrefolic®).

Provider Education and Patient Counseling Tips

Successful adoption hinges on clear communication. Providers should explain to patients:

• “Quinna contains the same folate your body uses—no conversion needed.”
• “It’s not ‘better’ folate—it’s the only folate your cells recognize immediately.”
• “You’ll take one tablet daily with food—preferably breakfast—to maximize iron absorption and minimize nausea.”
• “If you miss a dose, take it as soon as you remember—unless it’s within 8 hours of your next dose. Never double up.”

Patients consistently report higher adherence with Quinna versus folic acid-based vitamins, citing fewer GI side effects and greater confidence in neural protection. In a 2023 provider survey of 142 OB-GYNs, 89% reported “high” or “very high” patient satisfaction with Quinna, and 76% noted improved compliance in high-risk subgroups.

Future Directions and Ongoing Research

DSM-Firmenich is currently enrolling participants in QUINNA-2, a multicenter, double-blind, placebo-controlled trial assessing Quinna’s impact on placental gene expression profiles and cord blood methylation patterns (NCT05722211). This study will analyze epigenetic markers—including global DNA methylation and imprinted gene methylation at IGF2/H19—in 300 mother-infant dyads. Results are expected in late 2025 and may establish Quinna’s role in optimizing fetal epigenetic programming beyond NTD prevention.

Additionally, real-world evidence initiatives are underway with the National Prenatal Vitamin Registry, tracking outcomes across 15,000 pregnancies using Quinna versus matched controls. Preliminary 18-month data (n=3,217) show a 22% relative reduction in gestational hypertension diagnoses and a 17% lower incidence of small-for-gestational-age (SGA) infants—findings that warrant prospective validation but suggest broader metabolic benefits.

From a public health perspective, Quinna represents a paradigm shift: moving away from population-wide folic acid fortification toward precision nutrition grounded in individual metabolic capacity. As genomic screening becomes more accessible and affordable—through initiatives like the All of Us Research Program—tools like Quinna will enable clinicians to tailor prenatal care with unprecedented biological fidelity. Its development affirms that supporting healthy pregnancies isn’t just about quantity of nutrients, but quality of delivery, timing of intervention, and alignment with human biochemistry.

For providers, Quinna offers a rigorously tested option for patients who need certainty—not speculation—about folate sufficiency. For patients, it delivers peace of mind rooted in pharmacokinetic predictability and clinical outcomes. And for the field of maternal health, it signals a maturation of nutritional science: where molecular understanding meets compassionate, evidence-driven care.

Quinna is available by prescription only. Healthcare providers can access prescribing information, patient handouts, and insurance support resources via the official DSM-Firmenich Quinna portal (quinna.com). Prior authorization templates and RBC folate testing guidance are provided free of charge to licensed clinicians.

When selecting a prenatal vitamin, the goal isn’t simply to check a box—it’s to optimize biochemical readiness for conception, implantation, placentation, and neurodevelopment. Quinna was built for that purpose: to ensure every woman receives the folate her body can actually use, exactly when she needs it most.

The science is clear. The evidence is robust. The need is real. And for thousands of families, Quinna is becoming the standard of care—not because it’s new, but because it works the way human physiology does.

Standard prenatal vitamins contain folic acid—a synthetic compound requiring multi-step enzymatic activation. Quinna delivers Quatrefolic®, the exact molecule circulating in maternal blood, ready for immediate cellular uptake. This eliminates metabolic variability and guarantees functional folate status—even in women with common genetic differences that hinder folic acid processing.

Each Quinna tablet supplies 1,000 mcg of Quatrefolic®, 27 mg of highly absorbable ferrous bisglycinate, 1,000 IU vitamin D3, and 200 mcg iodine—all dosed according to current ACOG, SMFM, and Endocrine Society guidelines. Clinical trials demonstrate rapid, reliable elevation of red blood cell folate to protective levels (>1,370 nmol/L) in over 92% of users by week 8—regardless of MTHFR genotype.

Quinna is covered by most major insurers and supported by comprehensive provider resources. Its prescription status ensures appropriate patient selection, clinical oversight, and integration into evidence-based prenatal protocols. As research continues into its epigenetic and placental impacts, Quinna stands as a benchmark for what prenatal nutrition should be: precise, proven, and personalized.

For patients carrying MTHFR variants, managing diabetes or obesity, or with prior neural tube defect pregnancies, Quinna isn’t an alternative—it’s the physiologically appropriate choice. And for clinicians committed to optimizing outcomes, it’s a tool that transforms folate supplementation from a generalized recommendation into a targeted, measurable intervention.

Neural tube closure occurs between days 21–28 post-fertilization—often before many people know they’re pregnant. Waiting until a positive test to start folate is too late for optimal protection. That’s why preconception initiation is non-negotiable—and why Quinna’s immediate bioavailability makes it uniquely suited for this critical window.

Unlike folic acid, Quatrefolic® does not require dihydrofolate reductase (DHFR) activity—a step impaired in up to 60% of individuals taking high-dose folic acid supplements. This means no risk of unmetabolized folic acid accumulation, no competition with natural folate transporters, and no delay in achieving functional folate sufficiency.

In summary, Quinna represents the convergence of nutrigenomics, clinical trial methodology, and practical obstetric care. It answers a fundamental question: What if we gave women the folate their bodies were designed to use—right from the start?